Bruker (NASDAQ:BRKR – Get Free Report) had its price target lowered by stock analysts at Barclays from $69.00 to $65.00 in a research note issued on Monday,Benzinga reports. The firm currently has an ...

Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before ...

Bruker Corporation today announced the launch of the VERTEX NEO Platform today with its first product, the VERTEX NEO R. This ...

Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...

In a report released today, Brandon Couillard from Wells Fargo maintained a Buy rating on Bruker (BRKR – Research Report), with a price target ...

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bruker Corporation announced the launch of the LUMOS™ II ILIM , a quantum cascade laser (QCL) based infrared imaging ...

Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share.

Bruker ’s BRKR strong growth reflects its fundamental commitment to innovate high-value solutions and its ongoing portfolio transformation. Yet, the company’s operations face the wrath of excessive ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...